Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders

Biologics: Targets and Therapy

Volumn 1, Issue 2, 2007, Pages 129-138

  Mesa, Ruben A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Essential thrombocythemia; Myelofibrosis; Myeloproliferative diseases; Polycythemia vera; Therapy

Indexed keywords

EID: 83255181836     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. Apperley JF, Gardembas M, Melo JV, et al. 2002. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med, 347:481-7.
2. Baxter EJ, Scott LM, Campbell PJ, et al. 2005. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365:1054-61.
3. Borthakur G, Kantarjian H, Verstovsek S, et al. 2004. Imatinib mesylate therapy for patients (pts) with polycythemia vera (PV). ASH Annual Meeting Abstracts, 104:1527.
4. Cervantes F. 2001. Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: an update anno 2000. Pathol Biol (Paris), 49:148-52.
5. Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, et al. 2004. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol, 127:399-403.
6. Cervantes F, Hernandez-Boluda JC, Alvarez A, et al. 2000. Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica, 85:595-9.
7. Chang JC, Gross HM. 1988. Remission of chronic idiopathic myelofibro sis to busulfan treatment. American Journal of the Medical Sciences, 295:472-6.
8. Cools J, DeAngelo DJ, Gotlib J, et al. 2003a. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med, 348:1201-14.
9. Cools J, DeAngelo DJ, Gotlib J, et al. 2003b. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. [comment]. New England Journal of Medicine, 348:1201-14.
10. Cortelazzo S, Finazzi G, Ruggeri M, et al. 1995. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med, 332:1132-6.
11. Cortes J, Ault P, Koller C, et al. 2003. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood, 101:4714-16.
12. Cortes J, Giles F, O'Brien S, et al. 2003. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer, 97:2760-6.
13. Dameshek W. 1951. Some speculations on the myeloproliferative syndrome. Blood, 6:372-5.
14. Deeg HJ, Gooley TA, Flowers ME, et al. 2003. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood, 102:3912-18.
15. Devine SM, Hoffman R, Verma A, et al. 2002. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood, 99:2255-8.
16. Dingli D, Utz JP, Krowka MJ, et al. 2001. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest, 120:801-8.
17. Dobrzanski P, Hexner E, Serdikoff C, et al. 2006. CEP-701 is a JAK2 inhibitor which attenuates JAK2/STAT5 signaling pathway and the proliferation of primary cells from patients with myeloproliferative disorders. ASH Annual Meeting Abstracts, 108:3594.
18. Druker BJ, Talpaz M, Resta DJ, et al. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med, 344:1031-7.
19. Druker BJ, Tamura S, Buchdunger E, et al. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med, 2:561-6.
20. Dupriez B, Morel P, Demory JL, et al. 1996. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system [see comments]. Blood, 88:1013-18.
21. Elliott MA, Mesa RA, Tefferi A. 2002. Adverse events after imatinib mesylate therapy. N Engl J Med, 346:712-13.
22. Falanga A, Marchetti M, Vignoli A, et al. 2005. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol, 33:523-30.
23. Faoro LN, Tefferi A, Mesa RA. 2005. Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. Eur J Haematol, 74:117-20.
24. Finazzi G, Caruso V, Marchioli R, et al. 2005. Acute leukemia in poly-cythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood, 105:2664-70.
25. Giles F, Freedman SJ, Xiao A, et al. 2006. MK-0457, a novel multikinase inhibitor, has activity in refractory AML, including transformed JAK2 positive myeloproliferative disease (MPD), and in Philadelphia-positive ALL. ASH Annual Meeting Abstracts, 108:1967.
26. Gleich GJ, Leiferman KM, Pardanani A, et al. 2002. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet, 359:1577-8.
27. Grandage VL, Everington T, Linch DC, et al. 2006. Go6976 is a potent inhibitor of the JAK2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells. Br J Haematol, 135:303-16.
28. Guardiola P, Anderson JE, Bandini G, et al. 1999. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood, 93:2831-8.
29. Guardiola P, Esperou H, Cazalshatem D, et al. 1997. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. British Journal of Haematology, 98:1004-9.
30. Harrison CN, Campbell PJ, Buck G, et al. 2005. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med, 353:33-45.
31. Hasselbalch H. 2004. Imatinib mesylate in polycythemia vera. A hetero-geneous response pattern but a consistent reduction in phlebotomy requirements. ASH Annual Meeting Abstracts, 104:4747.
32. Hyjek E, Chadburn A, Cross NCP, et al. 2006. Correlation of clinical and molecular response to imatinib in polycythemia vera (PV) patients with bone marrow morphologic and immunophenotypic changes. ASH Annual Meeting Abstracts, 108:4914.
33. James C, Ugo V, Le Couedic JP, et al. 2005. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434:1144-8.
34. Jones AV, Higley K, Curtis C, et al. 2005. No significant molecular response in polycythemia vera patients treated with imatinib or interferon alpha. ASH Annual Meeting Abstracts, 106:373.
35. Kantarjian H, Sawyers C, Hochhaus A, et al. 2002. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med, 346:645-52.
36. Kralovics R, Passamonti F, Buser AS, et al. 2005. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med, 352:1779-90.
37. Kroger N, Zabelina T, Schieder H, et al. 2005. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. British Journal of Haematology, Published On-Line.
38. Kuriakose P, Shurafa MS. 2004. A phase II trial of imatinib mesylate (Gleevec(R)) in myeloproliferative disorders other than CML. ASH Annual Meeting Abstracts, 104:4765.
39. Kvasnicka HM, Thiele J. 2004. Bone marrow angiogenesis: methods of quantification and changes evolving in chronic myeloproliferative disorders. Histol Histopathol, 19:1245-60.
40. Landolfi R. 1998. Bleeding and thrombosis in myeloproliferative disorders. Current Opinion in Hematology, 5:327-31.
41. Landolfi R, Marchioli R, Kutti J, et al. 2004. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med, 350:114-24.
42. le Bousse-Kerdiles M, Desteke C, Guerton B, et al. 2005. Glivec/STI571 treatment stimulates megakaryopoiesis and normalizes PDGF receptor beta kinase expression in thrombocytopenic patients with myeloid metaplasia with myelofibrosis. Blood, 106:(abstr 2599).
43. Levine RL, Wadleigh M, Cools J. 2005. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myelofibrosis with myeloid metaplasia. Cancer Cell.
44. Li Z, Xu M, Xing S, et al. 2006. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem.
45. Lofvenberg E, Wahlin A, Roos G, et al. 1990. Reversal of myelofibrosis by hydroxyurea. European Journal of Haematology, 44:33-8.
46. Lombardo LJ, Lee FY, Chen P, et al. 2004. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methyl- pyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem, 47:6658-61.
47. Martinelli G, Cilloni D, Rondoni M, et al. 2005. Imatinib mesylate can induce molecular complete remission in idiopathic hypereosinophilic syndrome (HES). A phase II multicentric Italian clinical trial. ASH Annual Meeting Abstracts, 106:375.
48. Mesa RA. 2003. Myelofibrosis with myeloid metaplasia: therapeutic options in 2003. Curr Hematol Rep, 2:264-70.
49. Mesa RA, Hanson CA, Rajkumar SV, et al. 2000. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood, 96:3374-80.
50. Mesa RA, Powell H, Lasho T, et al. 2006. JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia. Leuk Res, 30:1457-60.
51. Mesa RA, Silverstein MN, Jacobsen SJ, et al. 1999. Population-based incidence and survival figures in essential thrombocythemia and agno-genic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol, 61:10-15.
52. Mesa RA, Verstovsek S, Cervantes F, et al. 2007. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res.
53. Najfeld V, Silver RT, Hoffman R, et al. 2004. Pretreatment cytogenetic abnormalities in polycythemia vera (PV) determines the effectivnes of imatinib: studies from a multi-institutional trial. ASH Annual Meeting Abstracts, 104:2431.
54. Nowell PC, Hungerford DA. 1960. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst, 25:85-109.
55. Pardanani A, Elliott M, Reeder T, et al. 2003. Imatinib for systemic mast-cell disease. Lancet, 362:535-6.
56. Pardanani A, Hood J, Lasho T, et al. 2006. TG101209, a selective JAK2 kinase inhibitor, suppresses endogenous and cytokine-supported colony formation from hematopoietic progenitors carrying JAK2V617F or MPLW515K/L mutations. ASH Annual Meeting Abstracts, 108:2680.
57. Pardanani A, Ketterling RP, Li CY, et al. 2006. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res, 30:965-70.
58. Pardanani A, Reeder T, Porrata LF, et al. 2003. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood, 101:3391-7.
59. Pardanani AD, Levine RL, Lasho T, et al. 2006. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood.
60. Pardanani AD, Reeder TL, Porrata LF, et al. 2002. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood, 27:27.
61. Passamonti F, Rumi E, Pungolino E, et al. 2004. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med, 117:755-61.
62. Petti MC, Latagliata R, Spadea T, et al. 2002. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol, 116:576-81.
63. Pikman Y, Lee BH, Mercher T, et al. 2006. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med, 3:e270.
64. Rondelli D, Barosi G, Bacigalupo A, et al. 2005. Allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in intermediate or high risk patients with myelofibrosis with myeloid metaplasia. Blood.
65. Ross TS, Bernard OA, Berger R, et al. 1998. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5; 7)(q33; q11.2). Blood, 91:4419-26.
66. Roy L, Guilhot J, Krahnke T, et al. 2006. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood, 108:1478-84.
67. Sayyah J, Ostrov D, Sayeski P. 2006. Identification and characterization of a novel Jak2 tyrosine kinase inhibitor. ASH Annual Meeting Abstracts, 108:3604.
68. Score J, Curtis C, Waghorn K, et al. 2006. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia, 20:827-32.
69. Scott LM, Tong W, Levine RL, et al. 2007. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med, 356:459-68.
70. Silver RT, Fruchtman SM, Feldman EJ, et al. 2004. Imatinib mesylate (GLEEVEC(R)) is effective in the treatment of polycythemia vera: a multi-institutional clinical trial. ASH Annual Meeting Abstracts, 104:656.
71. Stover EH, Chen J, Lee BH, et al. 2005. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood, 106:3206-13.
72. Tefferi A. 1998. The Philadelphia chromosome negative chronic myelo- proliferative disorders: a practical overview. Mayo Clinic Proceedings, 73:1177-84.
73. Tefferi A, Elliott MA, Pardanani A. 2006. Atypical myeloprolif- erative disorders: diagnosis and management. Mayo Clin Proc, 81:553-63.
74. Tefferi A, Jimenez T, Gray LA, et al. 2001. Radiation therapy for symp- tomatic hepatomegaly in myelofibrosis with myeloid metaplasia. Eur J Haematol, 66:37-42.
75. Tefferi A, Lasho TL, Schwager SM, et al. 2005. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol, 131:320-8.
76. Tefferi A, Mesa RA, Gray LA, et al. 2002. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood, 99:3854-6.
77. Tefferi A, Mesa RA, Nagorney DM, et al. 2000. Splenectomy in myelo-fibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood, 95:2226-33.
78. Tefferi A, Mesa RA, Schroeder G, et al. 2001. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol, 113:763-71.
79. Tefferi A, Patnaik MM, Pardanani A. 2006. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol, 133:468-92.
80. Theocharides A, Boissinot M, Garand R, et al. 2006. Myeloid blasts in transformed JAK2-V617F positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. ASH Annual Meeting Abstracts, 108:375.
81. van Genderen PJ, Michiels JJ. 1997. Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera. Seminars in Thrombosis and Hemostasis, 23:357-63.
82. Weisberg E, Manley P, Mestan J, et al. 2006. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer, 94:1765-9.
83. Wolanskyj AP, Schwager SM, McClure RF, et al. 2006. Essential thrombo-cythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc, 81:159-66.